TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28445231
Drug: Multi-Day Dosing
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-Day Dosing Group (n = 14)
Study: 28445231
Drug: Single Pre-Exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Pre-Exercise Dosing Group (n = 15)
Study: 22384612
Drug: Standard doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard doses of hMG (control group)
Study: 11122888
Drug: Increased dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased dose intensity during induction therapy
Study: 11122888
Drug: Purged autologous
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purged autologous bone marrow transplantation and standard chemotherapy consolidation
Study: 11122888
Drug: Autologous transplantation
Normalized name: Washed Microbiota Transplantation
DrugBank: Washed Microbiota Transplantation (DB15745)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous transplantation and chemotherapy
Study: 3571768
Drug: Bitolterol mesylate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bitolterol mesylate, 1.0 mg, administered three times daily for 3 months
Study: 3571768
Drug: Isoproterenol hydrochloride,
Normalized name: Isoproterenol Hydrochloride, 0.25% inhalation solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoproterenol hydrochloride, 1.5 mg, administered three times daily for 3 months
Study: 18302679
Drug: 2% minocycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% minocycline hydrochloride ointment applied once into the pocket
Study: 10761820
Drug: Other antipsychotic
Normalized name: Other antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other antipsychotic drugs
Study: 8872633
Drug: Thiorphan (inhaled,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiorphan (inhaled, 0.5 ml containing 1.25 mg/ml, administered by two inhalations)
Study: 20452781
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea ingestion (3 breakfast cups, 540 ml total)
Study: 19090602
Drug: Viscous fiber
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viscous fiber blend biscuits (10 g of highly viscous fiber blend)
Study: 19090602
Drug: Control biscuits
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control biscuits (50 g available carbohydrates)
Study: 19090602
Drug: White bread
Normalized name: White bread
Approvals — FDA: no, EMA: no, PMDA: no
Description: White bread with 12 g of margarine
Study: 2068950
Drug: Prednisone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (10 mg)
Study: 2068950
Drug: 1,25-dihydroxyvitamin D3
Normalized name: 1,25-dihydroxyvitamin D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,25-dihydroxyvitamin D3 (2 micrograms) + Prednisone (10 mg)
Study: 6631978
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of sexual awareness, relaxation and breathing (SARB group)
Study: 27373438
Drug: CHF6001 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF6001 400 μg
Study: 27373438
Drug: CHF6001 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF6001 1200 μg
Study: 11195234
Drug: Low-dose cisapride
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cisapride (0.1 mg/kg given 8 hourly)
Study: 9124832
Drug: Daily primaquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily primaquine (0.5 mg of base per kg of body weight per day)
Study: 9124832
Drug: Weekly chloroquine
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly chloroquine (300 mg of base one time per week)
Study: 1559542
Drug: rhGM-CSF (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGM-CSF (8 micrograms kg‐1) via intravenous (i.v.) bolus injection
Study: 1559542
Drug: rhGM-CSF (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGM-CSF (8 micrograms kg‐1) via subcutaneous (s.c.) bolus injection
Study: 3888863
Drug: Pre-trial medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-trial medication
Study: 26605752
Drug: Existing medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Existing medication guide prior to clinic visit (arm 1)
Study: 22158529
Drug: Nebulised bronchodilator
Normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised bronchodilator therapy driven by oxygen
Study: 22158529
Drug: Nebulised bronchodilator
Normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised bronchodilator therapy driven by air
Study: 15741029
Drug: Intra‐oral distraction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra‐oral distraction devices
Study: 15741029
Drug: Extra‐oral distraction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra‐oral distraction devices
Study: 10332685
Drug: Human insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human insulin (injected immediately before the meal)
Study: 10332685
Drug: Human insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human insulin (injected 30 min before the meal)
Study: 31492152
Drug: TAC monotherapy
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TAC monotherapy (n = 20)
Study: 24901809
Drug: 4.5 mg
Normalized name: phenol 14.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.5 mg · kg⁻¹ of caffeine
Study: 24901809
Drug: Placebo (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0 mg of caffeine per kg of body weight)
Study: 21602751
Drug: Propofol 6
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol 6 mg kg h(‐1) (Group P, N=20)
Study: 16142862
Drug: Intraarticular (IA)
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraarticular (IA) triamcinolone hexacetonide injection
Study: 16142862
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) triamcinolone acetonide mini-pulse therapy
Study: 10535229
Drug: Preparing for
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparing for the Drug‐Free Years program (PDFY)
Study: 7572244
Drug: Self-control therapy
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-control therapy program
Study: 2338632
Drug: SR-verapamil fasting
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR-verapamil fasting (1 X 240 mg)
Study: 2338632
Drug: SR-verapamil with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR-verapamil with food (1 X 240 mg)
Study: 2338632
Drug: Conventional formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional formulation of verapamil fasting (3 X 80 mg)
Study: 7448345
Drug: Quinidine formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine formulation 3
Study: 30423463
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids (15 x 300 mg capsules per day for 12 weeks)
Study: 23493643
Drug: Paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paliperidone palmitate (234 mg on day 1, 156 mg on day 8, then once-monthly flexible dosing)
Study: 23493643
Drug: Risperidone long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone long-acting injectable (RLAI) (25-50 mg biweekly, with oral risperidone supplementation on days 1-28)
Study: 21627523
Drug: Polysulfated glycosaminoglycan
Normalized name: polysulfated glycosaminoglycan
DrugBank: Polysulfated glycosaminoglycan (DB11538)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polysulfated glycosaminoglycan treatment (PSGAGT)
Study: 19862981
Drug: Warfarin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin with target INR of 1.50 to 1.99 (Group A)
Study: 19862981
Drug: Warfarin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin with target INR of 2.00 to 2.50 (Group B)
Study: 19862981
Drug: Warfarin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin with target INR of 2.51 to 3.00 (Group C)
Study: 19862981
Drug: Warfarin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin with target INR of 1.50 to 2.50 (Group A and B)
Study: 15169803
Drug: TAP (doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAP (doxorubicin 45 mg/m(2), cisplatin 50 mg/m(2), paclitaxel 160 mg/m(2) with filgrastim)
Study: 15169803
Drug: AP (doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: AP (doxorubicin 60 mg/m(2), cisplatin 50 mg/m(2))
Study: 8489566
Drug: Immediate release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release bezafibrate 300 mg dragee (A)
Study: 8489566
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release bezafibrate 400 mg dragee (B)
Study: 3318368
Drug: Mexiletine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexiletine (200 to 400 mg every 8 hours)
Study: 3318368
Drug: Quinidine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine (200 to 400 mg every 6 hours)
Study: 27162173
Drug: ASP015K (peficitinib)
Normalized name: peficitinib
DrugBank: Peficitinib (DB11708)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: ASP015K (peficitinib) 3 mg to 300 mg single dose
Study: 27162173
Drug: ASP015K (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP015K (30 mg) multiple doses
Study: 24998109
Drug: Fibrinogen concentrate
Normalized name: Fibrinogen concentrate human
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinogen concentrate (1g administered 30 min prior to operation)
Study: 22649162
Drug: Cognitive Sensory
Normalized name: SENSORY ORGANS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Sensory Motor Training Therapy (Perfetti's method)
Study: 10189646
Drug: 2% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine with 1:100,000 epinephrine diluted 1:9 with 0.9% bacteriostatic saline solution
Study: 25146009
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 3% mepivacaine plus 2% lidocaine with 1:100,000 epinephrine
Study: 25146009
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 2% lidocaine with 1:100,000 epinephrine plus 2% lidocaine with 1:100,000 epinephrine
Study: 22545190
Drug: SURG+systemic amoxicillin+systemic
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SURG+systemic amoxicillin+systemic metronidazole
Study: 15981555
Drug: Nebivolol (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol (target dose 5 mg)
Study: 10606909
Drug: Intraportal infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraportal infusion of lymphokine‐activated killer (LAK) cells combined with recombinant interleukin 2 (rIL‐2)
Study: 10606909
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (resection, IORT and LAK cells with rIL-2)
Study: 1734247
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone (1 g per day for 3 days, followed by oral prednisone 1 mg/kg/day for 11 days)
Study: 1734247
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone (1 mg/kg/day for 14 days)
Study: 26786575
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy group (74% experienced serious hypoglycemia)
Study: 26786575
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment group (21% experienced serious hypoglycemia)
Study: 20236094
Drug: Diphenhydramine 25
Normalized name: DIPHENHYDRAMINE 25MG CHEW TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine 25 mg i.v.
Study: 18519309
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment with a cast
Study: 16042226
Drug: IVIG (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG (1 g/kg body weight monthly for 27 months)
Study: 16042226
Drug: Placebo (albumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (albumin 0.1% monthly for 27 months)
Study: 8949805
Drug: Rocuronium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.6 mg kg‐1 (2xED95)
Study: 8949805
Drug: Rocuronium 0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.9 mg kg‐1 (3xED95)
Study: 29157034
Drug: Pregabalin plus
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin plus IV ibuprofen (150 mg pregabalin and 400 mg IV ibuprofen)
Study: 15182276
Drug: BUD +
Normalized name: Clove buds
DrugBank: Clove (DB10672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUD + M group (400 microg/day of inhaled budesonide plus 10 mg/day of montelukast)
Study: 15182276
Drug: High BUD
Normalized name: Clove buds
DrugBank: Clove (DB10672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High BUD group (800 microg/day of inhaled budesonide)
Study: 3302251
Drug: Nutritional supplement
Normalized name: Nutritional supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplement (multivitamin/multimineral) at high and low dosage
Study: 31665732
Drug: High-frequency repetitive
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-frequency repetitive transcranial magnetic stimulation (rTMS) targeting the left dorsolateral prefrontal cortex, 15 Hz, twice daily, 5 days/week for 2 weeks
Study: 21858663
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (tamsulosin + potassium citrate)
Study: 15477693
Drug: Intramuscular octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular octreotide LAR (20 mg initially, increased to 30 mg after 3 injections if mean GH levels >5 mU/l) administered every 28 days for 6 months
Study: 15477693
Drug: Subcutaneous octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous octreotide (50, 100 and 200 mug) administered in a randomized order on separate days prior to LAR therapy
Study: 15477693
Drug: Intramuscular octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular octreotide LAR
Study: 7884757
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g of a glucose polymer
Study: 25656621
Drug: Maraviroc 150
Normalized name: maraviroc 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maraviroc 150 mg daily plus lopinavir/ritonavir (MVC group)
Study: 18211302
Drug: Venlafaxine 75
Normalized name: venlafaxine 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine 75 mg extended release
Study: 10735921
Drug: omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: omeprazole 20 mg at 08:00 hours for 14 days
Study: 10735921
Drug: ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranitidine 300 mg at 22:00 hours for 14 days
Study: 4034850
Drug: Naloxone hydrochloride
Normalized name: Naloxone Hydrochloride
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naloxone hydrochloride (2 mg intravenous bolus)
Study: 4034850
Drug: Naloxone hydrochloride
Normalized name: Naloxone Hydrochloride
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naloxone hydrochloride (2 mg intravenous bolus) with estrogen (intramuscular 17-beta-estradiol)
Study: 23906186
Drug: Dexmedetomidine (DEX)
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine (DEX) at a dose of 1.0 μg/kg over 10 min followed by a continuous infusion of 0.5 μg/kg per hour
Study: 23906186
Drug: Sufentanil (SUF)
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sufentanil (SUF) target controlled infusion with a target plasma concentration of 0.3 ng/mL
Study: 12154100
Drug: Eplerenone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone (50 mg, increasing to 100 mg if required) once daily for 8 weeks
Study: 7884097
Drug: Oral pirenzepine
Normalized name: pirenzepine
DrugBank: Pirenzepine (DB00670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pirenzepine (25 mg twice daily)
Study: 2104624
Drug: Dexamethasone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (4 mg, iv)
Study: 2104624
Drug: Dexamethasone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (8 mg, orally)
Study: 2104624
Drug: Dexamethasone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (4 mg, iv) + Placebo
Study: 2104624
Drug: Dexamethasone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (4 mg, iv) + Atropine (0.5 mg, iv)
Study: 2104624
Drug: Dexamethasone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (4 mg, iv) + Pyridostigmine (120 mg, orally)
Study: 356578
Drug: Intramuscular lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular lidocaine (300 mg)
Study: 30904515
Drug: Real injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
DrugBank: Carboxymethylcellulose (DB11059)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real injection (hypertonic saline)
Study: 30904515
Drug: Sham injection
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham injection (no skin piercing)
Study: 28236348
Drug: Fixed time
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed time interval administration of tramadol, paracetamol, and diclofenac
Study: 28236348
Drug: On-demand administration
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-demand administration of tramadol, paracetamol, and diclofenac
Study: 15041715
Drug: Weekly docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly docetaxel (35 mg/m(2))
Study: 15041715
Drug: 3-weekly docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-weekly docetaxel (60 mg/m(2) with doxorubicin)
Study: 15041715
Drug: 3-weekly docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-weekly docetaxel (75 mg/m(2))
Study: 15041715
Drug: 3-weekly docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-weekly docetaxel (100 mg/m(2))
Study: 11106052
Drug: Intravenous ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous ibuprofen lysine (10 mg/kg, followed by 5 mg/kg after 24 and 48 h) within 24 h of life (group A)
Study: 11106052
Drug: Intravenous ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous ibuprofen lysine (10 mg/kg, followed by 5 mg/kg after 24 and 48 h) after echocardiographic diagnosis of PDA (group B)
Study: 8358406
Drug: methylphenidate (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: methylphenidate (0.3 mg/kg b.i.d.)
Study: 19375893
Drug: Ziprasidone 40
Normalized name: ziprasidone 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone 40 mg/d
Study: 19375893
Drug: Ziprasidone 80
Normalized name: ziprasidone 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone 80 mg/d
Study: 19375893
Drug: Ziprasidone 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone 120 mg/d
Study: 7901267
Drug: Protective agent
Normalized name: PROTECTIVE AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protective agent during short-term NSAID use
Study: 3096643
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin (Transiderm‐Nitro 25 mg/24 hours)
Study: 23533227
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone gel (2 doses targeting either 400-550 ng/dL or 600-1000 ng/dL)
Study: 20546622
Drug: Anti-platelet drug
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-platelet drug use (50% of diabetic patients)
Study: 20546622
Drug: Platelet inhibitor
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet inhibitor use (including aspirin and non-aspirin)
Study: 18811599
Drug: Darifenacin 7.5
Normalized name: darifenacin 7.5 MG
DrugBank: Darifenacin (DB00496)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Darifenacin 7.5 mg once daily (up-titrated to 15 mg after 2 weeks if needed) for up to 12 weeks
Study: 2097485
Drug: Fentanyl 20
Normalized name: fentaNYL 200 mcg buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 20 micrograms (0.4 ml) with 0.5% heavy marcaine 2.0 ml
Study: 2097485
Drug: Control group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group: 0.5% heavy marcaine 2.0 ml with CSF 0.4 ml
Study: 6457568
Drug: 2% solution
Normalized name: Lidomar 2% Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% solution of erythromycin
Study: 27119575
Drug: PD 0348292
Normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PD 0348292 (2.5-150 mg)
Study: 27119575
Drug: PD 0348292
Normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PD 0348292 (5-30 mg) every 12 hours
Study: 27119575
Drug: PD 0348292
Normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PD 0348292 (5 mg) single dose
Study: 25056151
Drug: Immediate therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate therapy group receiving physical therapy (maximum of 12 sessions of 30 min for a 6-week program)
Study: 25056151
Drug: Delayed therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed therapy group (6 weeks delay before starting therapy)